Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
285 Leser
Artikel bewerten:
(1)

YourBio Health launches nearly painless, at-home COVID-19 antibody test

YourBio Health launches website - www.yourbiohealth.com - to easily order an at-home COVID-19 antibody test that uses a nearly painless blood collection device

BOSTON, Sept. 13, 2021 /PRNewswire/ -- YourBio Health, formerly Seventh Sense Biosystems, Inc., developers of the world's first push-button blood collection device, announced the launch of its website where UK consumers can order a convenient, easy to use, nearly painless and accurate COVID-19 antibody test.

"We're happy to launch our COVID-19 antibody test service to UK consumers today," said Stephen Hahn, Chief Medical Officer (Interim). "At a time when monitoring COVID-19 and immune response is top of mind, we make it easy for consumers to assess and monitor their antibody response from the comfort and privacy of their own homes. What sets our test apart is that it uses YourBio Health's innovative device to draw blood that is both convenient and nearly painless."

While COVID-19 vaccines are highly effective some studies have suggested not all people retain vaccine antibodies for longer than a few weeks or months - potentially leaving them unknowingly at higher risk. Your Bio Health's COVID-19 test is the only lab-based service that can provide quantitative information about antibody levels without the need to prick fingers or have a venous sample taken. Knowing this could lead some to take more precautions about daily activity, or if available and appropriate, inquiring about a vaccine booster.

To minimize discomfort, YourBio Health's unique device is placed on the upper arm, to draw the blood sample. Once in position, activating the device is as simple as pressing a button. Rather than using a big needle or painful fingerpick lancets, a single press sends and retracts needles thinner than an eyelash into and out of the skin. Collecting a sample is mess-free and takes only about two minutes to complete. YourBio Health's device offers a distinct advantage to those squeamish, or with phobias of big needles. Results are delivered online to the consumer 24 hours after their sample is received at the lab, avoiding the hassle of scheduling appointments, driving to the collection center, and waiting in queue to administer the test.

"The launch of our website - yourbiohealth.com - is just the first step for transforming the way blood diagnostics are delivered," said Harry Wilcox, Executive Chairman of YourBio Health. "We're looking forward to increasing access to our device for additional tests in the U.S. and the U.K. and making it more widely available to patients and health care facilities."

The COVID-19 vaccine has already proven to be lifesaving and will continue to be central to the fight against COVID-19. However, by supplementing vaccine rollout efforts with antibody testing, instances where the vaccine may have reduced efficacy can be identified, monitored, and addressed. Antibody testing is central to these efforts and may help support the vaccine program to tackle new infections.

YourBio Health's antibody test has 98.8% sensitivity and 99.98% specificity[1], making it one of the most accurate and reliable tests available on the market. The test is currently available only in the UK and costs £99.99. Anyone can order a test to their own home by visiting www.yourbiohealth.com.

1. Elecsys Anti-SARS-CoV-2 S. Accessed 13 July 2021.
https://diagnostics.roche.com/gb/en/products/params/elecsys-anti-sars-cov-2-s.html

About YourBio Health

YourBio Health puts health information in the hands of the individual. As a direct-to-consumer brand that believes knowledge is power, we will offer convenient at-home testing so individuals can easily monitor their personal health information and make informed decisions about their lives. Backed by the latest science, technology, and certified central laboratories to guarantee best-in-class test results, the company's goal is to enable people to feel safe, confident, educated, and in control of their short and long-term health.

YourBio Health was founded by Flagship Pioneering, which conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $130 billion in aggregate value.

www.yourbiohealth.com

© 2021 PR Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.